MeiraGTx CEO Sells Shares Amid Positive Stock Performance and Strategic Developments
Meiragtx president & CEO Forbes Alexandria sells $568,540 in shares
Image: Investing Australia
Forbes Alexandria, President & CEO of MeiraGTx Holdings plc, sold 62,000 shares worth $568,540 on May 19, 2026. This insider sale follows a year where the stock rose by 66%, currently trading at $9.13. The company is also pursuing strategic collaborations and public offerings to support its gene therapy initiatives.
- 01The shares were sold at prices between $8.96 and $9.32, with a weighted average of $9.17.
- 02Following the sale, Forbes Alexandria retains 1,387,695 shares in MeiraGTx Holdings plc.
- 03MeiraGTx recently completed a collaboration with Hologen Limited to develop gene therapies for Parkinson’s disease and genetic obesity.
- 04The company is expecting to raise approximately $100 million through an underwritten public offering.
- 05Piper Sandler raised its price target for MeiraGTx to $30 based on positive three-year data from its xerostomia treatment.
Advertisement
In-Article Ad
On May 19, 2026, Forbes Alexandria, the President and CEO of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 62,000 ordinary shares of the company, totaling $568,540. The shares were sold under a Rule 10b5-1 trading plan, with prices ranging from $8.96 to $9.32 and a weighted average sale price of $9.17. This sale comes as MeiraGTx stock has appreciated 66% over the past year, currently trading at $9.13. Despite this growth, analysts indicate the stock may be slightly overvalued compared to its fair value estimates, which range from $19 to $50. Following the sale, Alexandria holds 1,387,695 shares of the company. Recently, MeiraGTx announced a strategic collaboration with Hologen Limited aimed at developing gene therapies for conditions such as Parkinson’s disease. Additionally, the company is planning to raise about $100 million through a public offering to fund its operations and potential product launches through 2028. Analysts have responded positively, with Piper Sandler increasing its price target to $30 based on favorable data from its xerostomia treatment, while RBC Capital raised its target to $24.
Advertisement
In-Article Ad
This insider sale and the company's strategic moves may influence investor confidence and stock performance, potentially affecting shareholders and market perception.
Advertisement
In-Article Ad
Reader Poll
Do you believe insider sales impact investor confidence?
Connecting to poll...
Read the original article
Visit the source for the complete story.